Cytomegalovirus (CMV) causes significant morbidity and mortality following allogeneic haemopoietic stem cell transplantation. A pre-emptive strategy for ganciclovir therapy is widely used, whereby treatment is commenced on finding positive evidence of CMV replication. Surveillance by PCR has increased the sensitivity for CMV detection, but it is not known whether this may detect cases with evidence of CMV DNAemia who have a low probability of CMV disease. We reviewed our experience of CMV infection and disease since introducing CMV surveillance by PCR. All 30 allografts received bedside leucodepleted CMV-negative blood products. Seven of 10 CMV-positive recipients of a CMV-positive graft developed CMV DNAemia, with three developing clinical disease requiring ganciclovir treatment. In contrast, of 11 low risk patients (CMVnegative recipients of CMV-negative grafts), six developed evidence of CMV DNAemia although only one had clinical evidence of CMV disease requiring ganciclovir. Transfusion records confirmed that four of these had received exclusively CMV-negative blood products. The aetiology of the CMV DNAemia in these cases is unclear. It is suggested that before commencing ganciclovir therapy, confirmatory CMV antigenaemia testing is carried out on samples which test positive for CMV DNA, unless there is high clinical suspicion of CMV disease. Bone Marrow Transplantation (2001) 27, 615-619.
morbidity and mortality in BMT recipients, causing particularly pneumonitis and gastrointestinal disease. Patients most at risk of CMV disease are CMV seronegative and receiving a graft from a CMV seropositive donor, or alternatively are CMV seropositive pre-BMT (irrespective of their donors CMV status). 2 Transplantation of a graft from an unrelated donor may confer a greater risk of CMV infection than grafts from siblings in adults 3, 4 although not in children. 5 Autograft recipients appear at lower risk of CMV disease, and post-autograft routine surveillance for CMV may not be justified. 6 Much work has been done on preventing CMV disease. In CMV seronegative recipients of a CMV seronegative graft, the incidence of CMV disease is minimal if CMVnegative blood products are used. 7 In one study, aciclovir prophylaxis, commenced at conditioning and continued for several months, was reported to reduce the mortality rate of CMV disease. 8 Prophylactic ganciclovir will decrease the incidence and severity of CMV disease, 9 although this is myelosuppressive, resulting in increased bacterial and fungal infection. In order to limit ganciclovir-induced myelosuppression, pre-emptive therapy is widely used, where ganciclovir is commenced on finding positive evidence of CMV in either broncho-alveolar lavage (BAL) fluid or blood in surveillance testing. Several studies have shown that introduction of ganciclovir therapy following positive evidence of CMV replication (eg positive cultures or the detection of leucocyte pp65 antigen) can reduce the incidence of CMV disease mortality. 10, 11 Recent data suggest that surveillance for CMV antigenaemia predicts CMV disease better than BAL or blood, throat or urine cultures, and has the advantage of being non-invasive. 12 CMV-derived DNA sequences may be detected in blood by polymerase chain reaction (PCR)-based techniques. [13] [14] [15] [16] [17] [18] [19] Pre-emptive treatment following detection of CMV DNAemia may reduce the incidence of CMV disease after BMT. 17 However, not all patients with CMV DNAemia go on to get CMV antigenaemia or CMV disease. 12, 14, 15 The technique may be too sensitive, and the clinical significance of finding CMV DNA in an otherwise healthy allograft recipient is not well understood.
We undertook the present analysis to investigate the feasibility of routine CMV surveillance in allograft recipients by screening for CMV DNAemia and the clinical relevance of a positive result for CMV DNA. Unlike CMV antigenaemia testing, surveillance by CMV DNAemia can be batched, and such a strategy may therefore be of practical help if batches are timed to coincide with a BMT outpatient clinic. We report a high frequency of CMV DNAemia in low risk allograft recipients, that (apart from a single case receiving CMV-positive platelets during an emergency) was not associated with CMV disease.
Patients and methods

Patient population
All allografts performed at our institution between January 1997 and May 1999 were included in the study. All patients received bone marrow, rather than peripheral blood stem cells. Clinical details are given in Table 1 venously twice daily from days Ϫ5 to ϩ4 inclusive, methotrexate with folinic acid rescue on each of days ϩ1, 3, 6 and 11, and cyclosporin A for 6 months. Fourteen of the 23 sibling transplants were T cell depleted by adding 10 mg of Campath-1G to the leucoconcentrated donor marrow, and in these cases no post-transplant immunosuppression was used. The remaining 11 T cell-replete sibling grafts received post-transplant immunosuppression with cyclosporin A for 6 months.
CMV prophylaxis
All patients received identical CMV prophylaxis with oral aciclovir 400 mg four times daily from admission to 6 months post allograft. 8 No patient received prophylactic gancicyclovir or CMV hyperimmune globulin. The transfusion policy throughout the study was that all patients should receive exclusively CMV-negative blood products (both red cells and platelets) from the local Blood Transfusion Centre, irrespective of donor or recipient CMV status. Blood products were assigned as CMV-negative by the Blood Transfusion Service if the donation tested as negative for CMV IgA, IgM and IgG antibody using the automated Abbott Commander instrument and the ELISAbased CMV Total AB EIA kit (Abbott Diagnostics, Abbott Park, IL, USA). All donations were screened for CMV, even if that donor had tested as negative on all previous donations. All blood products were leucodepleted at the bedside using a Sepacell filter (Asahi Medical Company, Tokyo, Japan).
CMV surveillance
All transplant recipients and donors were serologically tested pre-transplant for CMV antibody by an ELISA-based assay. Between January 1997 and July 1998 this was by VIDAS-CMVG (Biomerieux, Lyon, France), and from August 1998 until May 1999 by BIOELISA CMVIG (Biokit SA, Barcelona, Spain). CMV surveillance post transplant was performed on DNA extracted from EDTA anticoagulated blood by standard techniques. The PCRbased technique, primer sequences and probe details were as previously described (Ref. 9 , modified from Ref. 18 ). Samples were tested weekly for the first 3 months, then every 14 days for a further 3 months. CMV infection was defined as a positive PCR result during the surveillance period. Transient infection was defined as either a single positive CMV PCR result or more than one PCR-positive result on non-consecutive weeks. Persistent infection was defined as PCR positivity on consecutive weeks. CMV disease was defined as CMV infection in the setting of appropriate clinical findings Table 1 gives the CMV status of donor and recipient in each of the 30 cases. Eleven cases were low risk, with both donor and recipient serologically CMV-negative pre-transplant (RϪDϪ). The remaining cases were considered high risk if either donor, recipient or both tested as CMVpositive pre-transplant (RϪDϩ, RϩDϪ or RϩDϩ).
Results
The CMV PCR surveillance results for the study are shown in Table 2 . The RϩDϩ transplants had the highest proportion of CMV PCR positivity, with 7/10 developing either transient (five cases) or persistent (two cases) PCR positivity. Three of these seven cases had clinical features of CMV disease, and one of these had a positive CMV antigenaemia test. All three of these cases received ganciclovir, and made an uneventful recovery, with restoration of PCR negativity. However, six of 11 low risk (RϪDϪ) cases (55%) also became transiently (four cases) or persistently (two cases) PCR positive, and in none of these was Table 2 CMV infection and disease rates according to risk group RϪ ϭ recipient CMV negative; DϪ ϭ donor CMV negative; Rϩ ϭ recipient CMV positive; Dϩ ϭ donor CMV positive.
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there any evidence of CMV antigenaemia. Among these six cases, only one patient had clinical features compatible with CMV disease, and he remained persistently PCR positive. He was successfully treated with ganciclovir, with restoration of PCR negativity. In the low risk (RϪDϪ) cases, CMV status of blood products up to the time of PCR positivity was traced through transfusion laboratory records, in order to investigate whether CMV was acquired through post-BMT blood products (Table 3) . Two patients were found to have received CMV unscreened platelets, given during a haemorrhagic emergency. These platelets were transfused through a bedside filter. The blood donor of one of these units subsequently tested as CMV-positive at a later donation; the CMV status of the other blood donor remains unknown. The remaining four patients had exclusively received blood products stated as CMV seronegative.
Discussion
The present data demonstrate evidence of CMV infection in 55% of allograft recipients at low risk of CMV (donor and recipient both negative for CMV pre-transplant by ELISA). All cases received blood products depleted at the bedside. In two of these cases, it is possible that a single platelet transfusion was CMV-positive, but in all four remaining cases, all blood products were exclusively CMV seronegative. The source of CMV in these cases is unclear. Primary CMV infection is unlikely to account for all these cases, since the annual incidence of new infection is around 1% in adults, 20 and because all patients were restricted in their social interactions.
It is possible that CMV infection may have been transmitted by blood products post BMT. In support of this view are recent data that the risk of CMV antigenaemia may be less after PBSC allografting; 21 allogeneic PBSC recipients require less blood product support. A blood or bone marrow donor might have had CMV infection previously but may be a poor producer of CMV antibody and thus be incorrectly assigned as CMV-negative by techniques that rely on detecting CMV antibody such as ELISA. The recipients of blood products or marrow from such donors may therefore inadvertently receive CMV-positive products. This might be aggravated by the inherent false negative rate in the ELISA serological tests (approximately 1% for both kits used according to the manufacturer's product information). By the same argument, the BMT recipient might also test as a false negative on pre-BMT CMV screening. Many BMT patients have been immunosuppressed by previous chemotherapy, which may lead to a waning in the CMV antibody titre in a previously seropositive recipient. Such cases may be incorrectly assigned to a low risk group. It may be helpful to CMV screen all potential BMT recipients at original diagnosis. Assays including PCR are very sensitive, and are particularly prone to cross-contamination from other samples or from the operator. Scrupulous laboratory technique and control reactions are essential to minimise false positive results, and several guidelines have been produced to minimise PCR product carry-over. 22 The high sensitivity of PCR-based techniques may be a drawback to their usefulness in CMV surveillance. PCR may detect minute quantities of free CMV viral fragments that may be environmental or transfusion transmitted but lack pathogenicity, and therefore a positive PCR result may not be clinically relevant. It might be helpful to recommend that confirmatory CMV antigenaemia testing is carried out on samples which test positive for CMV DNA. Ganciclovir treatment is restricted to cases that are positive for CMV antigenaemia, unless there is a high degree of clinical suspicion of CMV disease. A recent report suggests that serial semi-quantitative PCR for CMV DNA may provide additional clinically relevant information, with both initial CMV load and rate of viral load increase being risk factors for CMV disease. 23 Bedside leucodepletion may reduce the transmission of CMV. 24 During the study period, leucodepletion was only carried out at the bedside. Leucodepletion 'at source' in the Blood Transfusion Centre may offer some advantages over bedside filtration, and is more amenable to quality control. 25 All blood products in the UK are now leucodepleted at source, with the aim of minimising the blood-borne transmission of new variant Creutzfeldt-Jacob disease. CMV unscreened bedside filtered blood products have been used as partial transfusion support in CMV seronegative recipients of CMV-negative grafts, with a 2.7% incidence of CMV infection. 26 It has been suggested that leucodepletion at source may substitute for CMV-negative blood products for BMT recipients (reviewed in Ref. 20) , although this is yet to be tested in a prospective trial. It will therefore be interesting to see the impact of leucodepletion at source on the incidence of CMV DNA positivity following allografting.
